Connect with us

International

Alkermes promotes from within to find new CFO and COO in rebound effort; Moderna vet Robert Dolski joins Checkmate as CFO

Iain Brown
→ Vowing to find a groove after a string of bogeys on the scorecard, Richard Pops has shaken up the C-suite at Alkermes, staying in-house by tapping Blair Jackson as COO and Iain Brown as CFO. Jackson, who began his tenure at Alkermes in…

Published

on

Iain Brown

→ Vowing to find a groove after a string of bogeys on the scorecard, Richard Pops has shaken up the C-suite at Alkermes, staying in-house by tapping Blair Jackson as COO and Iain Brown as CFO. Jackson, who began his tenure at Alkermes in 1999, moves up from the SVP post in corporate planning he held for 18 years. Continuing a run with Alkermes that dates to 2003, Brown was SVP and chief accounting officer prior to the promotion.

Brown replaces James Frates, who leaves Alkermes after nearly 20 years as the tottering biotech tries to regain its financial footing and looks to bounce back from a CRL handed down by the FDA in November for their anti-psychotic combo drug ALKS-3831. Alkermes didn’t fare much better in 2019, cutting 160 jobs and getting their depression drug ALKS-5461 brushed aside by the agency.

→ The new year brings two appointments to Art Krieg-founded Checkmate Pharmaceuticals, starting with CFO Robert Dolski. After working for Stéphane Bancel as Moderna’s VP, head of financial planning & analysis, Dolski heads to Cambridge, MA-based Checkmate after a brief stint as VP, finance at Akcea Therapeutics and not long after Checkmate closed on its $75 million IPO. Additionally, Katherine Eade has arrived as Checkmate’s general counsel. A member of Harvard Bioscience’s board of directors, Eade was previously with Align Technology as VP, strategic commercial affairs.

Artiva Biotherapeutics launched last summer with a $78 million Series A to fund their natural killer cell technology and move it forward to the clinic. Now founder Tom Farrell is transitioning out of the CEO role to chief strategy officer, while Fred Aslan takes his place. Aslan moves over to Artiva from his roles as president and CBO of Vividion Therapeutics, which just saw Diego Miralles pass the CEO torch to Jeffrey Hatfield. Aslan also co-founded and was a board member of Receptos Pharmaceuticals, purchased by Celgene in a 2015 deal worth $7.2 billion.

Richard Francis

Launched by Syncona back in November with a Series A in the neighborhood of $60 million (£45 million), University of Bristol spinout Purespring Therapeutics has selected Richard Francis as CEO. Francis ceded the top spot at Sandoz in March 2019, not willing to wait on the global revamp of Novartis’ generics division: “As we announced earlier this year, Sandoz is embarking on a significant transformation. While I am excited by this, I realize that this is a multi-year journey which I cannot commit to and therefore have decided that now is the right time to step down,” Francis said at the time.

Daphne Zohar has wooed George Farmer from the analyst ranks to back to the biotech trenches as CFO of PureTech. Farmer, who spent the past 15 years at BMO Capital Markets, had previously served as CEO of Cortice Biosciences and VP of corporate development at Synta Pharma, focusing on brain malignancies and cancer, respectively. He will now take over financial planning and reporting for PureTech, which has recently started listing on Nasdaq and initated three clinical trials.

Aida Habtezion

→ Following the authorization of the Covid-19 vaccine that was developed with BioNTech, Mace Rothenberg has decided to move on from his CMO post at Pfizer, with Stanford’s Aida Habtezion replacing him. Before taking over as CMO in January 2019, Rothenberg spent the previous dozen years as the pharma giant’s chief development officer for oncology. Habtezion, who arrived at “The Farm” in 2010 and has been an associate professor of medicine (gastroenterology and hepatology) at Stanford, has been given a second title at Pfizer: head of worldwide medical and safety.

Sung Lee

→ After earning the FDA’s approval in August with Monjuvi for refractory diffuse large B-cell lymphoma (DBLCL), MorphoSys has recruited Gilead alum Sung Lee as CFO. Lee, who leaves Sangamo behind after more than a year as their CFO, spent almost 14 years at Gilead from 2005-19 in a series of posts, eventually working his way up to SVP, financial planning & analysis and investor relations.

Lynn Seely has passed the CEO baton to Amgen vet David Marek, announcing her resignation on Sunday according to Myovant. Marek hops aboard from his most recent gig as CCO at Axsome Therapeutics. During his time at Amgen, Marek helped launch the migraine drug Aimovig, managed a pact with Novartis and led marketing for Amgen’s inflammation and nephrology unit. His other experiences span consumer service and advertising.

Ramona Doyle

→ Coming off a year in which it bagged a $239 million Series D and forged a partnership with Bayer, Recursion has made Ramona Doyle CMO. An ex-medical director at Gilead, Genentech and Roche, Doyle has also been CEO of telehealth nonprofit The MAVEN Project and is the former CMO at Blade Therapeutics.

→ As Nicole DeFeudis reported this week, Wei Lin has said farewell to Nektar, while immunology head Brian Kotzin has been named interim CMO and head of development. In his 11 years at Amgen, Kotzin was VP, global clinical development and head of the inflammation therapeutic area. He then moved to Nektar in 2017 to lead the immunology space at the San Francisco biotech, which discarded its opioid program NKTR-181 and sold the royalties to Adynovate and Movantik last year.

Wei Lin

→ As for Wei Lin? He says hello to Erasca, assuming the role of CMO at the Jonathan Lim-led oncology biotech that coaxed Genentech alum Michael Varney to be their R&D chairman last summer. Lin is a Genentech vet in his own right, having been global development lead in cancer immunotherapy for lung cancer and head and neck cancer before jumping to Nektar in 2018. Elsewhere at Erasca, CBO David Chacko will replace Gary Yeung as their CFO. Chacko, who came to Erasca in August 2019, was formerly a principal at Versant Ventures and chief of staff to the CEO at Alcon.

→ And what about Gary Yeung? To close the loop on this chain reaction of leadership changes, Yeung has headed to Ambrx to take on the dual roles of CFO and COO as the company moves its engineered precision biologics pipeline forward. As with Lin and Varney, Yeung brings experience from Genentech, where he held multiple titles over a 12-year period from 2004-16. After wrapping up his time at Genentech as senior director of program management, Yeung briefly occupied the position of VP, business and development operations for Annexon Biosciences.

William Kaelin

→ Along with cash and a prominent investor, LifeMine Therapeutics has reeled in Nobel laureate William Kaelin. Kaelin, who won the 2019 Noble Prize in physiology or medicine for his work in understanding how cells sense and adapt to changes in oxygen, is joining the board of directors at the company, co-founded by Rick Klausner.

→ Almost two decades after starting Celltrion, co-founder Seo Jung-jin has retired from his chairman role. Seo — the second richest man in Korea — is leaving the company, as reported by Korea Biomedical Review, for a stab at entrepreneurship before he retires, this time focusing on blood testing.

→ In connection to securing an $80 million Series C, DiCE Molecules has made the addition of Jake Simson to its board of directors. Simson is a partner at RA Capital Management and has served on the boards of Xenikos, Tyra Biosciences and AavantiBio.

→ San Diego protein degradation outfit BioTheryX has enlisted Robert Williamson as their new president and CEO, succeeding Celgene co-founder David Stirling. Williamson helmed old Celgene partner PharmAkea, which merged with Galecto a year ago at this time, as well as PharmAkea spinout ATXCo. A former board member at Pharmasset, Williamson has other CEO experience at Arriva Pharmaceuticals. BioTheryX announced their $35 million Series D round last summer to advance their acute myeloid leukemia drug BTX-A51.

→ Anti-inflammatory-focused Biomarck Pharmaceuticals has snagged Merck vet Graham Lumsden as president and CEO. Prior to joining the Durham, NC company, Lumsden was CEO of Motif Bio. In addition, Lumsden founded and was CEO of Tiemed.

Pamela Holland

Remy Durand has been promoted to CBO and Pamela Holland is on board as SVP, research at Seattle’s Alpine Immune Sciences, Mitch Gold’s crew that partnered with AbbVie on an $865 million deal for ALPN-101 in June. Durand gets bumped up from SVP of business development and corporate strategy, the position he took on when he joined Alpine in 2018. Holland worked in oncology research at Amgen from 2002-14, and since 2014 she’s held a series of roles at Surface Oncology, including the last 4 years as VP, cancer biology.

Ionis has promoted Eugene Schneider to chief clinical development officer, having him lead clinical development of antisense medicines throughout the company’s therapeutic franchises (Spinraza is one of the foremost examples of a drug developed with Ionis’ antisense technology). Schneider joined Ionis in 2013 as executive director, clinical development, neurology and rare diseases after being Synageva’s senior medical director, clinical R&D.

Anish Mehta

Anish Mehta has taken the CEO job at Dutch biotech Synthon and also occupies a spot as a board member. The Baxter vet had previously been chief executive at women’s health pharma Theramex from 2017-20, and before that, he logged 2 years as an exec at Allergan, serving as VP, international business development throughout Europe, the Middle East and Africa before leaving for Theramex.

→ A couple months after nabbing Brian O’Callaghan as CEO, ObsEva has tapped David Renas as CFO. He replaces Fabien de Ladonchamps, who had been CFO on an interim basis for ObsEva, the Swiss biotech jostling for position in the uterine fibroid race with AbbVie and Myovant. Like his boss O’Callaghan, Renas comes from Petra Pharma, where he filled the same CFO role. He’s also been CFO and general counsel at Sangart from 2002-14.

Scott Forrest

→ Raising the curtain in June with a $76 million round and backed by ARCH, Autobahn Therapeutics out of San Diego — focused on CNS diseases such as multiple sclerosis — has promoted Scott Forrest to CFO. Eagle-eyed Peer Review readers may remember Forrest took on the CBO job at the biotech in July. Before speeding into Autobahn, he was COO and CFO at Inception Therapeutics and co-founded BlackThorn Therapeutics. Meanwhile, GW Pharmaceuticals CFO Scott Giacobello has joined Autobahn’s board of directors.

David Richards

David Richards has taken the helm at Nationwide Children’s Hospital spinout Clarametyx Biosciences, which targets biofilm-associated infections. Richards replaces Michael Triplett, who keeps his seat on the company’s board of directors. Richards gets bumped up to CEO after starting as the CFO of Columbus, OH-based Clarametyx, which launched last year, and he was previously VP of corporate operations and general counsel for Aclipse Therapeutics. Additionally Larry Edwards, who took the CEO job at LaJolla Pharmaceutical after the Tetraphase deal, has joined Clarametyx’s board of directors.

Martin Brenner, who has an abundance of Big Pharma drug discovery and development experience with Eli Lilly, Pfizer, AstraZeneca and Merck, has joined Bryan, TX-based contract manufacturing organization iBio as their CSO. Brenner had been the chief scientist at Pfenex since March 2019, and also held the CSO post at Recursion for a short time. Elsewhere, he was the VP and head of R&D at Stoke Therapeutics.

Ke Liu

Steve Harr has boosted his leadership crew at Sana Biotechnology — one of the Endpoints 11 for 2020 — by bringing on longtime FDA vet Ke Liu as head of regulatory affairs & strategy. Liu spent 17 years at the agency, including the last 3 years as associate director for cell and gene therapy at the Oncology Center of Excellence. He had also been chief of oncology branch at the CBER’s Office of Tissues and Advanced Therapies (OTAT) since 2011. Elsewhere, Sana announced a trio of new board members, headlined by Loxo Oncology CEO Josh Bilenker. Joining Bilenker are Tectonic Therapeutic president and CEO Alise Reicin, and Russell Investments chairman and CEO Michelle Seitz.

→ Navigating the choppy waters of NASH, San Diego-based Viking Therapeutics is promoting Greg Zante to CFO and Marianne Mancini to COO. Zante, who came to Viking in 2016 as VP of finance and operations, has experience as a financial exec with Sangamo and, more recently, Dance Biopharm. Mancini started out with Viking as their VP of clinical operations in 2015, and her expertise in clinical operations has taken her to Baxter, Arena Pharmaceuticals and just before Viking, Ambit Biosciences.

Brendan Delaney

→ Cambridge, MA cancer biotech Constellation Pharmaceuticals has pegged Brendan Delaney to become its chief commercial officer, effective Jan 11. Delaney is completing his three-year tenure in the CCO gig at Immunomedics, which was acquired by Gilead this past fall for $21 billion. His pre-Immunomedics stops include marketing roles with Novartis and Genentech, along with six years as a marketing exec with Celgene.

Robert Habib-led MiNA Therapeutics, four months removed from pocketing a $30 million Series A round, has installed Robin Wright as CFO. Wright is the non-executive chairman of Oxford spinout Vaccitech, which co-developed the Covid-19 vaccine that AstraZeneca licensed. Wright’s CFO travels have also taken him to Pharming Group, Karolinska Development and Orexo.

Craig Tooman

→ London-based Silence Therapeutics continues its leadership retooling in 2021 after last year saw Mark Rothera take the helm as president and CEO. Silence has found Craig Tooman as CFO to replace Rob Quinn, who announced his departure in October. Tooman is on CureVac’s supervisory board and audit committee and he hails from Vyome Therapeutics, where he was CFO and COO. Prior to Vyome, he was CFO and later president and CEO of Aratana Therapeutics.

→ Chaired by Celgene co-founder Sol Barer, Gaithersburg, MD biotech NexImmune has welcomed fellow Celgene vet Jerome Zeldis into the fold as EVP, R&D. At Celgene — which was bought out by Bristol Myers Squibb for $74 billion, leaving a CVR mess behind — Zeldis was CMO and head of clinical research, medical affairs, and drug safety, as well as the CEO of Celgene Global Health. He’s also plied his CMO trade at Sorrento Therapeutics. In other NexImmune developments, Jeffrey Weber, deputy director of the Laura and Isaac Perlmutter Cancer Center at NYU Langone Health, will serve as chief scientific advisor.

James Kupiec

→ Austin, TX-based Alzheimer’s biotech Cassava Sciences has brought on James Kupiec as chief clinical development officer. Kupiec was at Pfizer for 17 years of his career (2000-17), serving as the pharma giant’s VP, global clinical leader for Parkinson’s disease and clinical head of the neuroscience research unit. He’s most recently been CMO at another neurodegenerative disorder biotech, ProMIS Neurosciences. In March 2019, Cassava put all their proverbial cards on the table and recalibrated fully to Alzheimer’s, changing their name from Pain Therapeutics after striking out on their opioid Remoxy.

Clinigenwhich bought the troubled IL-2 cancer drug, Proleukin, sold by Novartis back in 2018, has named Sam Herbert as COO.  He will be based in the UK. Prior to joining the company, Herbert was at World Courier, where he started as VP strategy, moving onto COO, before finally becoming president.

Brii Biosciences partner Qpex Biopharma, focused on ESBL enzymes with an anti-infective portfolio supported by BARDA, has corralled Paul Westberg as CBO. Westberg has also been CBO at Versartis, which merged with Aravive in 2018. After starting his career at Genentech, he would later be a business development exec at Novacea and Bayhill Therapeutics.

Clare Grace

→ CRO Parexel has created the new position of chief patient officer, “further demonstrating Parexel’s commitment to elevate the patient perspective so that their unique needs can be used to shape the conduct of future clinical studies,” according to the statement. It will be filled first by vet Clare Grace, who was previously Syneos Health’s VP, site & patient access. In the 2000s, Grace was a study delivery leader in non-small cell lung cancer for AstraZeneca.

→ In the wake of the late December reverse merger with NantKwest, California immunotherapy player ImmunityBio has appointed Fabio Benedetti as chief strategy officer. Before this latest endeavor at ImmunityBio — helmed by Patrick Soon-Shiong — Benedetti was CMO at Apollomics and global CMO at Taiho Pharmaceutical. He started his biopharma career as a medical director for Bristol Myers Squibb and Roche.

Dianne Whitfield

→ Irvine, CA-based Tarsus Pharmaceuticals had a busy 2020 with personnel changes — a new COO, CFO and CCO among them — and they pick up right where they left off by appointing Dianne Whitfield as chief human resources officer. Before heading to Tarsus, which is in Phase IIb/III with its lead drug for Demodex blepharitis, Whitfield was VP and head of human resources at Botox competitor Evolus, and from 2007-19 she held multiple HR roles at Allergan.

→ New Jersey-based biotech Celldex has promoted Freddy Jimenez to the position of SVP and general counsel. Jimenez joined the company in 2016 as VP, law and compliance. Prior to that, Jimenez had a 23-year stint at J&J.

Taysha Gene Therapies, which went public with a bang last year with a $157 million IPO just five months after its Series A financing, has recruited Greg Gara as SVP of manufacturing and Kimberly Lee as SVP of corporate communications and investor relations. Gara hails from Sarepta, where he was VP of pharmaceutical engineering. Prior to that, he served in roles at AveXis and Amgen. Meanwhile, Lee comes from Lexicon Pharmaceuticals, where she most recently served as head of corporate strategy and investor relations. Prior to that, she was at Raptor Pharmaceuticals and a sell-side analyst at Jefferies and Wedbush Securities.

→ Eye disease player Ocular Therapeutix out of Bedford, MA has promoted Michael Goldstein to president, ophthalmology, while calling upon Rabia Gurses Ozden to be SVP, clinical development. Goldstein leaps into the new position after three years as Ocular’s CMO, a title which he will keep. Ozden, who spent time at GSK as the pharma giant’s VP and head of clinical ophthalmology, had most recently held the chief development officer post at Akouos and is the ex-CMO of Nightstar Therapeutics.

Richard Law

Richard Law has been named EVP of strategic alliances at UK-based AI drug discovery biotech Exscientia, which just netted a $4.2 million grant from the Bill & Melinda Gates Foundation last month and raised $60 million from a Series C in May 2020. Law spent more than a dozen years at Evotec, including the last 7 ½ years as their SVP of business development.

→ After breaking in a new CMO, CFO and communications VP in 2020, personalized T cell therapy player Achilles Therapeutics is ringing in 2021 with Arjan Roozen as VP, site head and general manager. Roozen brings experience as chief technology officer at Zelluna Immunotherapy the last two years, and prior to his tenure there, he was VP, GMP solutions/manufacturing at Cellectis.

AbbVie partner Enanta Pharmaceuticals has followed up their December hire of Tara Kieffer with another appointment: VP of translational virology John DeVincenzo. He hails from Le Bonheur Children’s Hospital in Memphis and was medical director of the hospital’s Molecular Diagnostic and Virology Laboratories. DeVincenzo has also been a professor at the University of Tennessee College of Medicine.

Gregory Cosgrove

Pliant Therapeutics, the South San Francisco fibrosis specialist that joined the massive IPO parade of 2020 with a $144 million raise in May, has singled out Gregory Cosgrove to be their VP of clinical development, IPF (idiopathic pulmonary fibrosis). Cosgrove was previously CMO for the Pulmonary Fibrosis Foundation since 2014.

William Roberts has been selected as VP, investor relations & corporate communications at G1 Therapeutics, the oncology biotech out of the Research Triangle in North Carolina that changed CEOs from Mark Velleca to Jack Bailey effective Jan 1. The PDUFA date for G1’s trilaciclib is Feb 15. In the past, Roberts has been an investor relations director with MedImmune and an investor relations VP with Adaptimmune and Zynerba Pharmaceuticals.

DURECT, which received a split advisory panel vote on their non-opioid drug to manage post-surgical pain last year — has added two new members to its board of directors. The Cupertino, CA-based company welcomed Gail Maderis and Mohammad Azab to the fold. Maderis comes aboard after serving as president and CEO of Antiva Biosciences. In addition, she served as president and CEO of Five Prime Therapeutics and held roles at Genzyme. Meanwhile, Azab hails from Astex Pharmaceuticals, where he formerly served as president and CMO. Azab has also previously served in roles at AstraZeneca and Sanofi.

David Meeker

David Meeker, who signed on as CEO of Rhythm Pharmaceuticals last summer, has added chairman of Pharvaris to his list of titles. Elsewhere at Pharvaris, which back in November gathered up $80 million in a Series C used to target hereditary angioedema, OrbiMed partner Robert Glassman has also been added to the board.

Entrada Therapeutics — the startup launched by 5AM and MPM Capital to develop therapies based on a family of cell-penetrating small cyclic peptides that Ohio State professor Dehua Pei discovered — has made the addition of Peter Kim to its board of directors. Currently, Kim serves as a professor of biochemistry at Stanford University, institute scholar at Stanford ChEM-H and lead investigator of the infectious disease initiative at the Chan Zuckerberg Biohub. Previously, Kim was president of Merck Research Laboratories.

Selwyn Vickers

Forma Therapeutics, which went public this year and raised $320 million in large part on the strength of their Phase I/II sickle cell program, has appointed Selwyn Vickers to its board of directors. Vickers currently serves as SVP of medicine and dean of the School of Medicine at the University of Alabama at Birmingham.

Dave Johnson

→ Chaired by George Golumbeski, oncology player Aura Biosciences out of Cambridge, MA has welcomed ex-Acerta Pharma CEO Dave Johnson to the board of directors. Johnson founded and is CEO of VelosBio, which Merck bought for $2.75 billion two months ago in one of Roger Perlmutter’s valedictory moves.

→ Neurological and liver disease-focused gene therapy developer Apic Bio has made Stephen Hoffman chairman of the board. The ex-CEO of Aerpio Pharmaceuticals has other board seats at Dicerna and AcelRx to his credit.

Jing Marantz

→ Pittsburgh gene therapy player Krystal Biotech has expanded its board of directors with Chris Mason and Jing Marantz. Mason founded Avrobio in 2015 and is their CSO, while Marantz is Acceleron’s SVP and head of medical affairs.

James Sulat is now on the board of directors at Exicure, the gene expression biotech chaired by Tim Walbert that uses SNA (spherical nucleic acid) technology. Sulat, the former CEO of Maxygen and Memory Pharmaceuticals, is a board member at Valneva and Arch Therapeutics.

Kathleen LaPorte

Kathleen LaPorte has reserved a seat on the board of directors at Redwood City, CA immuno-oncology outfit Bolt Biotherapeutics, which last summer collected $93.5 million in a Series C led by Sofinnova Investments. LaPorte was the CEO of Nodality and is a board member at such companies as Elysium Therapeutics and Precipio Diagnostics.

Jnana Therapeutics — the biotech that billed itself as the first to focus solely and systematically on the solute carrier, or SLC transporter, family — has welcomed Annie Chen and Katalin Susztak to its scientific advisory board. Chen currently serves as CMO at Nimbus Therapeutics, while Susztak is a professor of medicine at the University of Pennsylvania Perelman School of Medicine.

→ A scientific advisory board has been assembled at Connect Biopharma, which scored a $115 million Series C in August 2020 that aids in development of CBP-307 (in Phase IIs for ulcerative colitis and Crohn’s disease) and CBP-201 (in Phase II for atopic dermatitis). The septet includes John Fahy, Brian Feagan, Emma Guttman-Yassky, Edward Kerwin, David Rubin, Bruce Strober and Stuart Swiedler.

Read More

Continue Reading

Government

Rand Paul Teases Senate GOP Leader Run – Musk Says “I Would Support”

Rand Paul Teases Senate GOP Leader Run – Musk Says "I Would Support"

Republican Kentucky Senator Rand Paul on Friday hinted that he may jump…

Published

on

Rand Paul Teases Senate GOP Leader Run - Musk Says "I Would Support"

Republican Kentucky Senator Rand Paul on Friday hinted that he may jump into the race to become the next Senate GOP leader, and Elon Musk was quick to support the idea. Republicans must find a successor for periodically malfunctioning Mitch McConnell, who recently announced he'll step down in November, though intending to keep his Senate seat until his term ends in January 2027, when he'd be within weeks of turning 86. 

So far, the announced field consists of two quintessential establishment types: John Cornyn of Texas and John Thune of South Dakota. While John Barrasso's name had been thrown around as one of "The Three Johns" considered top contenders, the Wyoming senator on Tuesday said he'll instead seek the number two slot as party whip. 

Paul used X to tease his potential bid for the position which -- if the GOP takes back the upper chamber in November -- could graduate from Minority Leader to Majority Leader. He started by telling his 5.1 million followers he'd had lots of people asking him about his interest in running...

...then followed up with a poll in which he predictably annihilated Cornyn and Thune, taking a 96% share as of Friday night, with the other two below 2% each. 

Elon Musk was quick to back the idea of Paul as GOP leader, while daring Cornyn and Thune to follow Paul's lead by throwing their names out for consideration by the Twitter-verse X-verse. 

Paul has been a stalwart opponent of security-state mass surveillance, foreign interventionism -- to include shoveling billions of dollars into the proxy war in Ukraine -- and out-of-control spending in general. He demonstrated the latter passion on the Senate floor this week as he ridiculed the latest kick-the-can spending package:   

In February, Paul used Senate rules to force his colleagues into a grueling Super Bowl weekend of votes, as he worked to derail a $95 billion foreign aid bill. "I think we should stay here as long as it takes,” said Paul. “If it takes a week or a month, I’ll force them to stay here to discuss why they think the border of Ukraine is more important than the US border.”

Don't expect a Majority Leader Paul to ditch the filibuster -- he's been a hardy user of the legislative delay tactic. In 2013, he spoke for 13 hours to fight the nomination of John Brennan as CIA director. In 2015, he orated for 10-and-a-half-hours to oppose extension of the Patriot Act

Rand Paul amid his 10 1/2 hour filibuster in 2015

Among the general public, Paul is probably best known as Capitol Hill's chief tormentor of Dr. Anthony Fauci, who was director of the National Institute of Allergy and Infectious Disease during the Covid-19 pandemic. Paul says the evidence indicates the virus emerged from China's Wuhan Institute of Virology. He's accused Fauci and other members of the US government public health apparatus of evading questions about their funding of the Chinese lab's "gain of function" research, which takes natural viruses and morphs them into something more dangerous. Paul has pointedly said that Fauci committed perjury in congressional hearings and that he belongs in jail "without question."   

Musk is neither the only nor the first noteworthy figure to back Paul for party leader. Just hours after McConnell announced his upcoming step-down from leadership, independent 2024 presidential candidate Robert F. Kennedy, Jr voiced his support: 

In a testament to the extent to which the establishment recoils at the libertarian-minded Paul, mainstream media outlets -- which have been quick to report on other developments in the majority leader race -- pretended not to notice that Paul had signaled his interest in the job. More than 24 hours after Paul's test-the-waters tweet-fest began, not a single major outlet had brought it to the attention of their audience. 

That may be his strongest endorsement yet. 

Tyler Durden Sun, 03/10/2024 - 20:25

Read More

Continue Reading

International

‘I couldn’t stand the pain’: the Turkish holiday resort that’s become an emergency dental centre for Britons who can’t get treated at home

The crisis in NHS dentistry is driving increasing numbers abroad for treatment. Here are some of their stories.

This clinic in the Turkish resort of Antalya is the official 'dental sponsor' of the Miss England competition. Diana Ibanez-Tirado, Author provided

It’s a hot summer day in the Turkish city of Antalya, a Mediterranean resort with golden beaches, deep blue sea and vibrant nightlife. The pool area of the all-inclusive resort is crammed with British people on sun loungers – but they aren’t here for a holiday. This hotel is linked to a dental clinic that organises treatment packages, and most of these guests are here to see a dentist.

From Norwich, two women talk about gums and injections. A man from Wales holds a tissue close to his mouth and spits blood – he has just had two molars extracted.

The dental clinic organises everything for these dental “tourists” throughout their treatment, which typically lasts from three to 15 days. The stories I hear of what has caused them to travel to Turkey are strikingly similar: all have struggled to secure dental treatment at home on the NHS.

“The hotel is nice and some days I go to the beach,” says Susan*, a hairdresser in her mid-30s from Norwich. “But really, we aren’t tourists like in a proper holiday. We come here because we have no choice. I couldn’t stand the pain.”

Seaside beach resort with mountains in the distance
The Turkish Mediterranean resort of Antalya. Akimov Konstantin/Shutterstock

This is Susan’s second visit to Antalya. She explains that her ordeal started two years earlier:

I went to an NHS dentist who told me I had gum disease … She did some cleaning to my teeth and gums but it got worse. When I ate, my teeth were moving … the gums were bleeding and it was very painful. I called to say I was in pain but the clinic was not accepting NHS patients any more.

The only option the dentist offered Susan was to register as a private patient:

I asked how much. They said £50 for x-rays and then if the gum disease got worse, £300 or so for extraction. Four of them were moving – imagine: £1,200 for losing your teeth! Without teeth I’d lose my clients, but I didn’t have the money. I’m a single mum. I called my mum and cried.

Susan’s mother told her about a friend of hers who had been to Turkey for treatment, then together they found a suitable clinic:

The prices are so much cheaper! Tooth extraction, x-rays, consultations – it all comes included. The flight and hotel for seven days cost the same as losing four teeth in Norwich … I had my lower teeth removed here six months ago, now I’ve got implants … £2,800 for everything – hotel, transfer, treatments. I only paid the flights separately.

In the UK, roughly half the adult population suffers from periodontitis – inflammation of the gums caused by plaque bacteria that can lead to irreversible loss of gums, teeth, and bone. Regular reviews by a dentist or hygienist are required to manage this condition. But nine out of ten dental practices cannot offer NHS appointments to new adult patients, while eight in ten are not accepting new child patients.

Some UK dentists argue that Britons who travel abroad for treatment do so mainly for cosmetic procedures. They warn that dental tourism is dangerous, and that if their treatment goes wrong, dentists in the UK will be unable to help because they don’t want to be responsible for further damage. Susan shrugs this off:

Dentists in England say: ‘If you go to Turkey, we won’t touch you [afterwards].’ But I don’t worry because there are no appointments at home anyway. They couldn’t help in the first place, and this is why we are in Turkey.

‘How can we pay all this money?’

As a social anthropologist, I travelled to Turkey a number of times in 2023 to investigate the crisis of NHS dentistry, and the journeys abroad that UK patients are increasingly making as a result. I have relatives in Istanbul and have been researching migration and trading patterns in Turkey’s largest city since 2016.

In August 2023, I visited the resort in Antalya, nearly 400 miles south of Istanbul. As well as Susan, I met a group from a village in Wales who said there was no provision of NHS dentistry back home. They had organised a two-week trip to Turkey: the 12-strong group included a middle-aged couple with two sons in their early 20s, and two couples who were pensioners. By going together, Anya tells me, they could support each other through their different treatments:

I’ve had many cavities since I was little … Before, you could see a dentist regularly – you didn’t even think about it. If you had pain or wanted a regular visit, you phoned and you went … That was in the 1990s, when I went to the dentist maybe every year.

Anya says that once she had children, her family and work commitments meant she had no time to go to the dentist. Then, years later, she started having serious toothache:

Every time I chewed something, it hurt. I ate soups and soft food, and I also lost weight … Even drinking was painful – tea: pain, cold water: pain. I was taking paracetamol all the time! I went to the dentist to fix all this, but there were no appointments.

Anya was told she would have to wait months, or find a dentist elsewhere:

A private clinic gave me a list of things I needed done. Oh my God, almost £6,000. My husband went too – same story. How can we pay all this money? So we decided to come to Turkey. Some people we know had been here, and others in the village wanted to come too. We’ve brought our sons too – they also need to be checked and fixed. Our whole family could be fixed for less than £6,000.

By the time they travelled, Anya’s dental problems had turned into a dental emergency. She says she could not live with the pain anymore, and was relying on paracetamol.

In 2023, about 6 million adults in the UK experienced protracted pain (lasting more than two weeks) caused by toothache. Unintentional paracetamol overdose due to dental pain is a significant cause of admissions to acute medical units. If left untreated, tooth infections can spread to other parts of the body and cause life-threatening complications – and on rare occasions, death.

In February 2024, police were called to manage hundreds of people queuing outside a newly opened dental clinic in Bristol, all hoping to be registered or seen by an NHS dentist. One in ten Britons have admitted to performing “DIY dentistry”, of which 20% did so because they could not find a timely appointment. This includes people pulling out their teeth with pliers and using superglue to repair their teeth.

In the 1990s, dentistry was almost entirely provided through NHS services, with only around 500 solely private dentists registered. Today, NHS dentist numbers in England are at their lowest level in a decade, with 23,577 dentists registered to perform NHS work in 2022-23, down 695 on the previous year. Furthermore, the precise division of NHS and private work that each dentist provides is not measured.

The COVID pandemic created longer waiting lists for NHS treatment in an already stretched public service. In Bridlington, Yorkshire, people are now reportedly having to wait eight-to-nine years to get an NHS dental appointment with the only remaining NHS dentist in the town.

In his book Patients of the State (2012), Argentine sociologist Javier Auyero describes the “indignities of waiting”. It is the poor who are mostly forced to wait, he writes. Queues for state benefits and public services constitute a tangible form of power over the marginalised. There is an ethnic dimension to this story, too. Data suggests that in the UK, patients less likely to be effective in booking an NHS dental appointment are non-white ethnic groups and Gypsy or Irish travellers, and that it is particularly challenging for refugees and asylum-seekers to access dental care.


This article is part of Conversation Insights
The Insights team generates long-form journalism derived from interdisciplinary research. The team is working with academics from different backgrounds who have been engaged in projects aimed at tackling societal and scientific challenges.


In 2022, I experienced my own dental emergency. An infected tooth was causing me debilitating pain, and needed root canal treatment. I was advised this would cost £71 on the NHS, plus £307 for a follow-up crown – but that I would have to wait months for an appointment. The pain became excruciating – I could not sleep, let alone wait for months. In the same clinic, privately, I was quoted £1,300 for the treatment (more than half my monthly income at the time), or £295 for a tooth extraction.

I did not want to lose my tooth because of lack of money. So I bought a flight to Istanbul immediately for the price of the extraction in the UK, and my tooth was treated with root canal therapy by a private dentist there for £80. Including the costs of travelling, the total was a third of what I was quoted to be treated privately in the UK. Two years on, my treated tooth hasn’t given me any more problems.

A better quality of life

Not everyone is in Antalya for emergency procedures. The pensioners from Wales had contacted numerous clinics they found on the internet, comparing prices, treatments and hotel packages at least a year in advance, in a carefully planned trip to get dental implants – artificial replacements for tooth roots that help support dentures, crowns and bridges.

Street view of a dental clinic in Antalya, Turkey
Dental clinic in Antalya, Turkey. Diana Ibanez-Tirado, CC BY-NC-ND

In Turkey, all the dentists I speak to (most of whom cater mainly for foreigners, including UK nationals) consider implants not a cosmetic or luxurious treatment, but a development in dentistry that gives patients who are able to have the procedure a much better quality of life. This procedure is not available on the NHS for most of the UK population, and the patients I meet in Turkey could not afford implants in private clinics back home.

Paul is in Antalya to replace his dentures, which have become uncomfortable and irritating to his gums, with implants. He says he couldn’t find an appointment to see an NHS dentist. His wife Sonia went through a similar procedure the year before and is very satisfied with the results, telling me: “Why have dentures that you need to put in a glass overnight, in the old style? If you can have implants, I say, you’re better off having them.”

Most of the dental tourists I meet in Antalya are white British: this city, known as the Turkish Riviera, has developed an entire economy catering to English-speaking tourists. In 2023, more than 1.3 million people visited the city from the UK, up almost 15% on the previous year.


Read more: NHS dentistry is in crisis – are overseas dentists the answer?


In contrast, the Britons I meet in Istanbul are predominantly from a non-white ethnic background. Omar, a pensioner of Pakistani origin in his early 70s, has come here after waiting “half a year” for an NHS appointment to fix the dental bridge that is causing him pain. Omar’s son had been previously for a hair transplant, and was offered a free dental checkup by the same clinic, so he suggested it to his father. Having worked as a driver for a manufacturing company for two decades in Birmingham, Omar says he feels disappointed to have contributed to the British economy for so long, only to be “let down” by the NHS:

At home, I must wait and wait and wait to get a bridge – and then I had many problems with it. I couldn’t eat because the bridge was uncomfortable and I was in pain, but there were no appointments on the NHS. I asked a private dentist and they recommended implants, but they are far too expensive [in the UK]. I started losing weight, which is not a bad thing at the beginning, but then I was worrying because I couldn’t chew and eat well and was losing more weight … Here in Istanbul, I got dental implants – US$500 each, problem solved! In England, each implant is maybe £2,000 or £3,000.

In the waiting area of another clinic in Istanbul, I meet Mariam, a British woman of Iraqi background in her late 40s, who is making her second visit to the dentist here. Initially, she needed root canal therapy after experiencing severe pain for weeks. Having been quoted £1,200 in a private clinic in outer London, Mariam decided to fly to Istanbul instead, where she was quoted £150 by a dentist she knew through her large family. Even considering the cost of the flight, Mariam says the decision was obvious:

Dentists in England are so expensive and NHS appointments so difficult to find. It’s awful there, isn’t it? Dentists there blamed me for my rotten teeth. They say it’s my fault: I don’t clean or I ate sugar, or this or that. I grew up in a village in Iraq and didn’t go to the dentist – we were very poor. Then we left because of war, so we didn’t go to a dentist … When I arrived in London more than 20 years ago, I didn’t speak English, so I still didn’t go to the dentist … I think when you move from one place to another, you don’t go to the dentist unless you are in real, real pain.

In Istanbul, Mariam has opted not only for the urgent root canal treatment but also a longer and more complex treatment suggested by her consultant, who she says is a renowned doctor from Syria. This will include several extractions and implants of back and front teeth, and when I ask what she thinks of achieving a “Hollywood smile”, Mariam says:

Who doesn’t want a nice smile? I didn’t come here to be a model. I came because I was in pain, but I know this doctor is the best for implants, and my front teeth were rotten anyway.

Dentists in the UK warn about the risks of “overtreatment” abroad, but Mariam appears confident that this is her opportunity to solve all her oral health problems. Two of her sisters have already been through a similar treatment, so they all trust this doctor.

Alt text
An Istanbul clinic founded by Afghan dentists has a message for its UK customers. Diana Ibanez-Tirado, CC BY-NC-ND

The UK’s ‘dental deserts’

To get a fuller understanding of the NHS dental crisis, I’ve also conducted 20 interviews in the UK with people who have travelled or were considering travelling abroad for dental treatment.

Joan, a 50-year-old woman from Exeter, tells me she considered going to Turkey and could have afforded it, but that her back and knee problems meant she could not brave the trip. She has lost all her lower front teeth due to gum disease and, when I meet her, has been waiting 13 months for an NHS dental appointment. Joan tells me she is living in “shame”, unable to smile.

In the UK, areas with extremely limited provision of NHS dental services – known as as “dental deserts” – include densely populated urban areas such as Portsmouth and Greater Manchester, as well as many rural and coastal areas.

In Felixstowe, the last dentist taking NHS patients went private in 2023, despite the efforts of the activist group Toothless in Suffolk to secure better access to NHS dentists in the area. It’s a similar story in Ripon, Yorkshire, and in Dumfries & Galloway, Scotland, where nearly 25,000 patients have been de-registered from NHS dentists since 2021.

Data shows that 2 million adults must travel at least 40 miles within the UK to access dental care. Branding travel for dental care as “tourism” carries the risk of disguising the elements of duress under which patients move to restore their oral health – nationally and internationally. It also hides the immobility of those who cannot undertake such journeys.

The 90-year-old woman in Dumfries & Galloway who now faces travelling for hours by bus to see an NHS dentist can hardly be considered “tourism” – nor the Ukrainian war refugees who travelled back from West Sussex and Norwich to Ukraine, rather than face the long wait to see an NHS dentist.

Many people I have spoken to cannot afford the cost of transport to attend dental appointments two hours away – or they have care responsibilities that make it impossible. Instead, they are forced to wait in pain, in the hope of one day securing an appointment closer to home.

Billboard advertising a dental clinic in Turkey
Dental clinics have mushroomed in recent years in Turkey, thanks to the influx of foreign patients seeking a wide range of treatments. Diana Ibanez-Tirado, CC BY-NC-ND

‘Your crisis is our business’

The indignities of waiting in the UK are having a big impact on the lives of some local and foreign dentists in Turkey. Some neighbourhoods are rapidly changing as dental and other health clinics, usually in luxurious multi-storey glass buildings, mushroom. In the office of one large Istanbul medical complex with sections for hair transplants and dentistry (plus one linked to a hospital for more extensive cosmetic surgery), its Turkish owner and main investor tells me:

Your crisis is our business, but this is a bazaar. There are good clinics and bad clinics, and unfortunately sometimes foreign patients do not know which one to choose. But for us, the business is very good.

This clinic only caters to foreign patients. The owner, an architect by profession who also developed medical clinics in Brazil, describes how COVID had a major impact on his business:

When in Europe you had COVID lockdowns, Turkey allowed foreigners to come. Many people came for ‘medical tourism’ – we had many patients for cosmetic surgery and hair transplants. And that was when the dental business started, because our patients couldn’t see a dentist in Germany or England. Then more and more patients started to come for dental treatments, especially from the UK and Ireland. For them, it’s very, very cheap here.

The reasons include the value of the Turkish lira relative to the British pound, the low cost of labour, the increasing competition among Turkish clinics, and the sheer motivation of dentists here. While most dentists catering to foreign patients are from Turkey, others have arrived seeking refuge from war and violence in Syria, Iraq, Afghanistan, Iran and beyond. They work diligently to rebuild their lives, careers and lost wealth.

Regardless of their origin, all dentists in Turkey must be registered and certified. Hamed, a Syrian dentist and co-owner of a new clinic in Istanbul catering to European and North American patients, tells me:

I know that you say ‘Syrian’ and people think ‘migrant’, ‘refugee’, and maybe think ‘how can this dentist be good?’ – but Syria, before the war, had very good doctors and dentists. Many of us came to Turkey and now I have a Turkish passport. I had to pass the exams to practise dentistry here – I study hard. The exams are in Turkish and they are difficult, so you cannot say that Syrian doctors are stupid.

Hamed talks excitedly about the latest technology that is coming to his profession: “There are always new materials and techniques, and we cannot stop learning.” He is about to travel to Paris to an international conference:

I can say my techniques are very advanced … I bet I put more implants and do more bone grafting and surgeries every week than any dentist you know in England. A good dentist is about practice and hand skills and experience. I work hard, very hard, because more and more patients are arriving to my clinic, because in England they don’t find dentists.

Dental equipment in a Turkish treatment room
Dentists in Turkey boast of using the latest technology. Diana Ibanez-Tirado, CC BY-NC-ND

While there is no official data about the number of people travelling from the UK to Turkey for dental treatment, investors and dentists I speak to consider that numbers are rocketing. From all over the world, Turkey received 1.2 million visitors for “medical tourism” in 2022, an increase of 308% on the previous year. Of these, about 250,000 patients went for dentistry. One of the most renowned dental clinics in Istanbul had only 15 British patients in 2019, but that number increased to 2,200 in 2023 and is expected to reach 5,500 in 2024.

Like all forms of medical care, dental treatments carry risks. Most clinics in Turkey offer a ten-year guarantee for treatments and a printed clinical history of procedures carried out, so patients can show this to their local dentists and continue their regular annual care in the UK. Dental treatments, checkups and maintaining a good oral health is a life-time process, not a one-off event.

Many UK patients, however, are caught between a rock and a hard place – criticised for going abroad, yet unable to get affordable dental care in the UK before and after their return. The British Dental Association has called for more action to inform these patients about the risks of getting treated overseas – and has warned UK dentists about the legal implications of treating these patients on their return. But this does not address the difficulties faced by British patients who are being forced to go abroad in search of affordable, often urgent dental care.

A global emergency

The World Health Organization states that the explosion of oral disease around the world is a result of the “negligent attitude” that governments, policymakers and insurance companies have towards including oral healthcare under the umbrella of universal healthcare. It as if the health of our teeth and mouth is optional; somehow less important than treatment to the rest of our body. Yet complications from untreated tooth decay can lead to hospitalisation.

The main causes of oral health diseases are untreated tooth decay, severe gum disease, toothlessness, and cancers of the lip and oral cavity. Cases grew during the pandemic, when little or no attention was paid to oral health. Meanwhile, the global cosmetic dentistry market is predicted to continue growing at an annual rate of 13% for the rest of this decade, confirming the strong relationship between socioeconomic status and access to oral healthcare.

In the UK since 2018, there have been more than 218,000 admissions to hospital for rotting teeth, of which more than 100,000 were children. Some 40% of children in the UK have not seen a dentist in the past 12 months. The role of dentists in prevention of tooth decay and its complications, and in the early detection of mouth cancer, is vital. While there is a 90% survival rate for mouth cancer if spotted early, the lack of access to dental appointments is causing cases to go undetected.

The reasons for the crisis in NHS dentistry are complex, but include: the real-term cuts in funding to NHS dentistry; the challenges of recruitment and retention of dentists in rural and coastal areas; pay inequalities facing dental nurses, most of them women, who are being badly hit by the cost of living crisis; and, in England, the 2006 Dental Contract that does not remunerate dentists in a way that encourages them to continue seeing NHS patients.

The UK is suffering a mass exodus of the public dentistry workforce, with workers leaving the profession entirely or shifting to the private sector, where payments and life-work balance are better, bureaucracy is reduced, and prospects for career development look much better. A survey of general dental practitioners found that around half have reduced their NHS work since the pandemic – with 43% saying they were likely to go fully private, and 42% considering a career change or taking early retirement.

Reversing the UK’s dental crisis requires more commitment to substantial reform and funding than the “recovery plan” announced by Victoria Atkins, the secretary of state for health and social care, on February 7.

The stories I have gathered show that people travelling abroad for dental treatment don’t see themselves as “tourists” or vanity-driven consumers of the “Hollywood smile”. Rather, they have been forced by the crisis in NHS dentistry to seek out a service 1,500 miles away in Turkey that should be a basic, affordable right for all, on their own doorstep.

*Names in this article have been changed to protect the anonymity of the interviewees.


For you: more from our Insights series:

To hear about new Insights articles, join the hundreds of thousands of people who value The Conversation’s evidence-based news. Subscribe to our newsletter.

Diana Ibanez Tirado receives funding from the School of Global Studies, University of Sussex.

Read More

Continue Reading

International

Beloved mall retailer files Chapter 7 bankruptcy, will liquidate

The struggling chain has given up the fight and will close hundreds of stores around the world.

Published

on

It has been a brutal period for several popular retailers. The fallout from the covid pandemic and a challenging economic environment have pushed numerous chains into bankruptcy with Tuesday Morning, Christmas Tree Shops, and Bed Bath & Beyond all moving from Chapter 11 to Chapter 7 bankruptcy liquidation.

In all three of those cases, the companies faced clear financial pressures that led to inventory problems and vendors demanding faster, or even upfront payment. That creates a sort of inevitability.

Related: Beloved retailer finds life after bankruptcy, new famous owner

When a retailer faces financial pressure it sets off a cycle where vendors become wary of selling them items. That leads to barren shelves and no ability for the chain to sell its way out of its financial problems. 

Once that happens bankruptcy generally becomes the only option. Sometimes that means a Chapter 11 filing which gives the company a chance to negotiate with its creditors. In some cases, deals can be worked out where vendors extend longer terms or even forgive some debts, and banks offer an extension of loan terms.

In other cases, new funding can be secured which assuages vendor concerns or the company might be taken over by its vendors. Sometimes, as was the case with David's Bridal, a new owner steps in, adds new money, and makes deals with creditors in order to give the company a new lease on life.

It's rare that a retailer moves directly into Chapter 7 bankruptcy and decides to liquidate without trying to find a new source of funding.

Mall traffic has varied depending upon the type of mall.

Image source: Getty Images

The Body Shop has bad news for customers  

The Body Shop has been in a very public fight for survival. Fears began when the company closed half of its locations in the United Kingdom. That was followed by a bankruptcy-style filing in Canada and an abrupt closure of its U.S. stores on March 4.

"The Canadian subsidiary of the global beauty and cosmetics brand announced it has started restructuring proceedings by filing a Notice of Intention (NOI) to Make a Proposal pursuant to the Bankruptcy and Insolvency Act (Canada). In the same release, the company said that, as of March 1, 2024, The Body Shop US Limited has ceased operations," Chain Store Age reported.

A message on the company's U.S. website shared a simple message that does not appear to be the entire story.

"We're currently undergoing planned maintenance, but don't worry we're due to be back online soon."

That same message is still on the company's website, but a new filing makes it clear that the site is not down for maintenance, it's down for good.

The Body Shop files for Chapter 7 bankruptcy

While the future appeared bleak for The Body Shop, fans of the brand held out hope that a savior would step in. That's not going to be the case. 

The Body Shop filed for Chapter 7 bankruptcy in the United States.

"The US arm of the ethical cosmetics group has ceased trading at its 50 outlets. On Saturday (March 9), it filed for Chapter 7 insolvency, under which assets are sold off to clear debts, putting about 400 jobs at risk including those in a distribution center that still holds millions of dollars worth of stock," The Guardian reported.

After its closure in the United States, the survival of the brand remains very much in doubt. About half of the chain's stores in the United Kingdom remain open along with its Australian stores. 

The future of those stores remains very much in doubt and the chain has shared that it needs new funding in order for them to continue operating.

The Body Shop did not respond to a request for comment from TheStreet.   

Read More

Continue Reading

Trending